Screener
Summit Therapeutics SMMT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Summit Therapeutics’s 10-Q, filed August 6, 2024. Open the filing →
- Filed
- Aug 6, 2024
- Fiscal quarter
- Q2 FY2024
- Calendar quarter
- Q2 2024
- Accession
- 0001599298-24-000117
FAQ
- What is Summit Therapeutics's EBITDA margin?
- Summit Therapeutics (SMMT) reported EBITDA margin of -267,925.5% in Q2 2023.
- How has Summit Therapeutics's EBITDA margin changed year-over-year?
- Summit Therapeutics's EBITDA margin decreased by 6829.4% year-over-year, from -3,866.5% to -267,925.5%.
- What is the long-term trend for Summit Therapeutics's EBITDA margin?
- Over 2 years (2020 to 2022), Summit Therapeutics's EBITDA margin has grown at a 29.3% compound annual growth rate (CAGR), from -6,004.8% to -10,046.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Summit Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude